drugset / Trial / NCT06830343
The Safety, Tolerability, and Pharmacokinetics of of SYH9017 in Chinese Participants With Overweight and Obesity
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a randomized, double-blind, single-center, dose-escalation, single ascending dose and multiple ascending dose study of SYH9017 in Chinese participants with overweight and obesity.
Timeline
- Start
- 2025-02-27
- Primary completion
- 2026-08-01
- Completion
- 2026-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SYH9017 | Unknown | — | Subcutaneous |
| Comparator | Semaglutide | Peptide | — | — |